Skip to main content

Table 3 Logistic regression of factors involved in the development of KTD

From: Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients

 

Bivariate analysis

Multivariate analysis

OR

(95% CI)

p

OR

(95% CI)

p

Female vs male

0,814

0,336

1974

0,650

    

Caucasian vs Non-Caucasian

1883

0,304

11,684

0,497

    

Baseline age (per yrs)

0,989

0,956

1023

0,524

    

BMI ≤18 vs > 18

1133

0,335

3840

0,841

    

TDF as part of first ARV regimen vs TDF as part of second or further ARV regimens

0,341

0,162

0,715

0,004

1040

0,195

5537

0,963

Previous therapy duration (per yrs)

1057

0,988

1131

0,110

0,948

0,854

1051

0,309

Baseline CD4 cell count (per cells/mL)

1000

0,999

1001

0,907

    

Baseline Plasma HIV-RNA level (per log cps/mL)

0,793

0,677

0,929

0,004

0,809

0,578

1132

0,216

HCV coinfection

1444

0,505

4131

0,493

    

Baseline creatinine (per mg/dL)

1999

0,138

28,861

0,611

    

Duration of treatment with TDF (per months)

1006

0,998

1015

0,162

0,998

0,987

1009

0,672

Use of protease inhibitors

0,823

0,396

1712

0,602

    

Hypertension

2039

0,769

5405

0,152

0,991

0,318

3084

0,987

Diabetes

2477

0,714

8595

0,153

3670

0,914

14,740

0,067

Bone diseasea

3178

1529

6603

0,002

3147

1361

7279

0,007

ABCC2–24 C > T (CC vs CT/TT)

0,689

0,332

1428

0,316

    

ABCC4 3463 A > G (GG vs AG/AA)

4667

1247

17,464

0,022

2663

0,610

11,621

0,193

ABCC10 rs2125739 T > C (CC vs TC/TT)

0,530

0,111

2525

0,425

    
  1. Abbreviations: OR odds ratio, CI confidence interval, cps copies, yrs. years, BMI body mass index, KTD kidney tubular dysfunction, ABCC ATP-binding cassette, ARV antiretroviral therapy; aosteopenia/osteoporosis; TDF tenofovir diproxil fumarate; p values are for χ2